Changes in the Serum Urate Level Can Predict the Development of Parkinsonism in the 6-Hydroxydopamine Animal Model.

Changes in the Serum Urate Level Can Predict the Development of Parkinsonism in the 6-Hydroxydopamine Animal Model. Neurochem Res. 2018 Apr 03;: Authors: Sarukhani MR, Haghdoost-Yazdi H, Khandan-Chelarci G Abstract Epidemiological studies indicate that a higher plasma level of uric acid (UA) associates with the reduced risk of Parkinson's disease (PD). To confirm the role of UA as a biomarker for PD, we evaluated changes in the serum UA level in the 6-hydroxydopamine (6-OHDA)-induced hemiparkinsonism in rat. For this purpose, 6-OHDA was administered in the medial forebrain bundle by stereotaxic surgery. According to the apomorphine-induced rotational test, the increased intensity of behavioral symptoms as a function of time was associated with the further reduction of UA level. On the other hand, the level of UA increased in the midbrain of the injured hemisphere. The level of reduction in the serum UA level of rats with severe and moderate symptoms was significantly higher than that of rats with mild symptoms. The immunohistofluorescence and biochemical analyses showed that the serum UA level was also correlated with the death of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra pars compacta (SNc), reduced level of striatal dopamine, and severity of oxidative stress in the midbrain. The rats with mild symptoms also showed a significant decrease in TH-positive neurons and striatal dopamine level. These findings suggest a positive correl...
Source: Neurochemical Research - Category: Neuroscience Authors: Tags: Neurochem Res Source Type: research

Related Links:

We present the case of a woman with DBS as a treatment for PD, safely treated with ECT for a psychotic depression. Depression severity and motor changes were evaluated on a weekly basis using the Montgomery-Åsberg Depression Rating Scale and the Unified Parkinson's Disease Rating Scale. During the course of ECT, the Montgomery-Åsberg Depression Rating Scale score declined from 34 to 13, and the Unified Parkinson's Disease Rating Scale motor score from 44 to 12 with positive impact on rigidity. Considering the positive impact of ECT on the motor function in our patient, new research should look into ECT as an au...
Source: The Journal of ECT - Category: Psychiatry Tags: Case Reports Source Type: research
New MRI technique reveals iron accumulations that could lead to Parkinson ’s dementia prediction.
Source: Diagnostic Imaging - Category: Radiology Authors: Tags: Brain MRI Dementia Parkinsons Disease Source Type: news
Publication date: Available online 20 February 2020Source: Journal of Electroanalytical ChemistryAuthor(s): Ya Ma, Qiong Hu, Cheng Liu, Lishi WangAbstractIn this manuscript, a nanospherical conjugated microporous polymer (CMP) was synthesized. This material together with graphene nanosheets (GS) was used as electrode modification materials to construct a molecularly imprinted electrochemical sensor for high sensitivity detection of α-Synuclein (α-Syn). The MIP sensor was synthesized by electropolymerization pyrrole and characterized by scanning electron microscopy (SEM), cyclic voltammetry (CV) and differential...
Source: Journal of Electroanalytical Chemistry - Category: Chemistry Source Type: research
Conditions:   Dystonia Disorder;   Parkinson Disease Interventions:   Drug: Botulinum toxin type A;   Drug: Placebo Sponsors:   University of Calgary;   Allergan Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Neural implants may provide treatment options for a wide variety of ailments, including Parkinson’s and epilepsy, but such devices have to work for long periods of time in a very difficult environment inside the cranium. One challenge is provid...
Source: Medgadget - Category: Medical Devices Authors: Tags: Materials Neurology Neurosurgery Source Type: blogs
BACKGROUND: Nocturnal hypokinesia commonly affects Parkinson's disease (PD) patients, manifesting primarily as an impaired ability to turn in bed and sleeping in specific positions, such as prone that potentially poses the risk of positional asphyxia. ...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
Conditions:   Dystonia Disorder;   Parkinson Disease Interventions:   Drug: Botulinum toxin type A;   Drug: Placebo Sponsors:   University of Calgary;   Allergan Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 19 February 2020Source: International Journal of PharmaceuticsAuthor(s): Subrat K. Bhattamisra, Angeline S. Tzeyung, Lim Wen Xi, Nurul Hasyanazifa Safian, Hira Choudhury, Lim Wei Meng, Naiyer Shahzad, Nabil A. Alhakamy, Md khalid Anwer, Ammu K. Radhakrishnan, Shadab MdAbstractRotigotine, a non-ergoline dopamine agonist, has been shown to be highly effective for the treatment of Parkinson's disease (PD). However, despite its therapeutic potential, its’ clinical applications were hindered due to low aqueous solubility, first-pass metabolism and low bioavailability. Therefore, we devel...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
THURSDAY, Feb. 20, 2020 -- Love to cross-country ski? Well, all those days spent striding across the snow-covered wilderness may do more than keep you in great physical shape. Swedish researchers report that very fit long-distance skiers were about...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
No abstract available
Source: Neurology Today - Category: Neurology Tags: In the Pipeline Source Type: research
More News: Brain | Epidemiology | Neurology | Neuroscience | Neurosurgery | Parkinson's Disease | Study